Industry Research Reports

Home > Reports > Medical Care > Gastrointestinal Cancer Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Gastrointestinal Cancer Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Medical Care

Published Date: 2026-07-14

Pages: 137 Pages

Report ld: 6938888

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Gastrointestinal Cancer Treatment Market Size(US$)

CAGR 2026-2032

12.6%

Market Size,2032

USD 12,720

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 6,255 million

Market Forecast in 2032(Value)

US$ 12,720 million

CAGR

12.6%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Gastrointestinal Cancer Treatment was estimated to be worth US$ 5619 million in 2025 and is projected to reach US$ 12720 million, growing at a CAGR of 12.6% from 2026 to 2032.

Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report provides a comprehensive view of the global market for Gastrointestinal Cancer Treatment, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Gastrointestinal Cancer Treatment market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Cancer Treatment.

Market Segmentation

By Company

Eli Lilly
F. Hoffmann
GlaxoSmithKline
Merck
Novartis AG
Otsuka Holdings
Stryker Corporation
Boston Scientific Corporation
Johnson and Johnson
CONMED Corporation
Bristol-Myers Squibb
Pfizer
Celltrion Inc
Amgen Limited
Celgene Corporation
Sanofi
Mylan N.V.
Samsung Bioepis
Teva Pharmaceutical Industries Ltd.

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Surgery
Targeted Drugs Therapy
Chemo Therapy
Adjuvant Chemotherapy
Radiation Therapy

Segment by Application

Hospitals
Clinics
Research Centers
Others

biaoTi Chapter Outline

Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.

Chapter 2: Provides a detailed analysis of the Gastrointestinal Cancer Treatment companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents Gastrointestinal Cancer Treatment revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents Gastrointestinal Cancer Treatment revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.

Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi Why This Report?

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

Table of Contents

1 Market Overview

1.1 Gastrointestinal Cancer Treatment Product Introduction

1.2 Global Gastrointestinal Cancer Treatment Market Size Forecast (2021–2032)

1.3 Gastrointestinal Cancer Treatment Market Trends & Drivers

1.3.1 Gastrointestinal Cancer Treatment Industry Trends

1.3.2 Gastrointestinal Cancer Treatment Market Drivers & Opportunities

1.3.3 Gastrointestinal Cancer Treatment Market Challenges

1.3.4 Gastrointestinal Cancer Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Gastrointestinal Cancer Treatment Players Revenue Ranking (2025)

2.2 Global Gastrointestinal Cancer Treatment Revenue by Company (2021–2026)

2.3 Key Companies’ R&D and Operations Footprint and Headquarters

2.4 Key Companies Gastrointestinal Cancer Treatment Product Offerings

2.5 Key Companies General Availability (GA) Timeline for Gastrointestinal Cancer Treatment

2.6 Gastrointestinal Cancer Treatment Market Competitive Analysis

2.6.1 Gastrointestinal Cancer Treatment Market Concentration Rate (2021–2026)

2.6.2 Top 5 and Top 10 Global Companies by Gastrointestinal Cancer Treatment Revenue in 2025

2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Gastrointestinal Cancer Treatment revenue, 2025

2.7 Mergers & Acquisitions and Expansion

3 Segmentation Gastrointestinal Cancer Treatment Market Classification

3.1 Introduction by Type

3.1.1 Surgery

3.1.2 Targeted Drugs Therapy

3.1.3 Chemo Therapy

3.1.4 Adjuvant Chemotherapy

3.1.5 Radiation Therapy

3.1.6 Global Gastrointestinal Cancer Treatment Sales Value by Type

3.1.6.1 Global Gastrointestinal Cancer Treatment Sales Value by Type (2021 vs 2025 vs 2032)

3.1.6.2 Global Gastrointestinal Cancer Treatment Sales Value, by Type (2021–2032)

3.1.6.3 Global Gastrointestinal Cancer Treatment Sales Value, by Type (%), 2021–2032

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals

4.1.2 Clinics

4.1.3 Research Centers

4.1.4 Others

4.2 Global Gastrointestinal Cancer Treatment Sales Value by Application

4.2.1 Global Gastrointestinal Cancer Treatment Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global Gastrointestinal Cancer Treatment Sales Value by Application (2021–2032)

4.2.3 Global Gastrointestinal Cancer Treatment Sales Value by Application (%), 2021–2032

5 Segmentation by Region

5.1 Global Gastrointestinal Cancer Treatment Sales Value by Region

5.1.1 Global Gastrointestinal Cancer Treatment Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global Gastrointestinal Cancer Treatment Sales Value by Region (2021–2026)

5.1.3 Global Gastrointestinal Cancer Treatment Sales Value by Region (2027–2032)

5.1.4 Global Gastrointestinal Cancer Treatment Sales Value by Region (%), 2021–2032

5.2 North America

5.2.1 North America Gastrointestinal Cancer Treatment Sales Value, 2021–2032

5.2.2 North America Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

5.3 Europe

5.3.1 Europe Gastrointestinal Cancer Treatment Sales Value, 2021–2032

5.3.2 Europe Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

5.4 Asia Pacific

5.4.1 Asia Pacific Gastrointestinal Cancer Treatment Sales Value, 2021–2032

5.4.2 Asia Pacific Gastrointestinal Cancer Treatment Sales Value by Subregion (%), 2025 vs 2032

5.5 South America

5.5.1 South America Gastrointestinal Cancer Treatment Sales Value, 2021–2032

5.5.2 South America Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

5.6 Middle East & Africa

5.6.1 Middle East & Africa Gastrointestinal Cancer Treatment Sales Value, 2021–2032

5.6.2 Middle East & Africa Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Gastrointestinal Cancer Treatment Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.3 United States

6.3.1 United States Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.3.2 United States Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.3.3 United States Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.4.2 Europe Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.5.2 China Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.5.3 China Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.6.2 Japan Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.7.2 South Korea Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.8.2 Southeast Asia Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India Gastrointestinal Cancer Treatment Sales Value, 2021–2032

6.9.2 India Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

6.9.3 India Gastrointestinal Cancer Treatment Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 Eli Lilly

7.1.1 Eli Lilly Profile

7.1.2 Eli Lilly Main Business

7.1.3 Eli Lilly Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.1.4 Eli Lilly Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.1.5 Eli Lilly Recent Developments

7.2 F. Hoffmann

7.2.1 F. Hoffmann Profile

7.2.2 F. Hoffmann Main Business

7.2.3 F. Hoffmann Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.2.4 F. Hoffmann Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.2.5 F. Hoffmann Recent Developments

7.3 GlaxoSmithKline

7.3.1 GlaxoSmithKline Profile

7.3.2 GlaxoSmithKline Main Business

7.3.3 GlaxoSmithKline Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.3.4 GlaxoSmithKline Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.3.5 GlaxoSmithKline Recent Developments

7.4 Merck

7.4.1 Merck Profile

7.4.2 Merck Main Business

7.4.3 Merck Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.4.4 Merck Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.4.5 Merck Recent Developments

7.5 Novartis AG

7.5.1 Novartis AG Profile

7.5.2 Novartis AG Main Business

7.5.3 Novartis AG Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.5.4 Novartis AG Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.5.5 Novartis AG Recent Developments

7.6 Otsuka Holdings

7.6.1 Otsuka Holdings Profile

7.6.2 Otsuka Holdings Main Business

7.6.3 Otsuka Holdings Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.6.4 Otsuka Holdings Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.6.5 Otsuka Holdings Recent Developments

7.7 Stryker Corporation

7.7.1 Stryker Corporation Profile

7.7.2 Stryker Corporation Main Business

7.7.3 Stryker Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.7.4 Stryker Corporation Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.7.5 Stryker Corporation Recent Developments

7.8 Boston Scientific Corporation

7.8.1 Boston Scientific Corporation Profile

7.8.2 Boston Scientific Corporation Main Business

7.8.3 Boston Scientific Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.8.4 Boston Scientific Corporation Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.8.5 Boston Scientific Corporation Recent Developments

7.9 Johnson and Johnson

7.9.1 Johnson and Johnson Profile

7.9.2 Johnson and Johnson Main Business

7.9.3 Johnson and Johnson Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.9.4 Johnson and Johnson Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.9.5 Johnson and Johnson Recent Developments

7.10 CONMED Corporation

7.10.1 CONMED Corporation Profile

7.10.2 CONMED Corporation Main Business

7.10.3 CONMED Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.10.4 CONMED Corporation Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.10.5 CONMED Corporation Recent Developments

7.11 Bristol-Myers Squibb

7.11.1 Bristol-Myers Squibb Profile

7.11.2 Bristol-Myers Squibb Main Business

7.11.3 Bristol-Myers Squibb Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.11.4 Bristol-Myers Squibb Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.11.5 Bristol-Myers Squibb Recent Developments

7.12 Pfizer

7.12.1 Pfizer Profile

7.12.2 Pfizer Main Business

7.12.3 Pfizer Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.12.4 Pfizer Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.12.5 Pfizer Recent Developments

7.13 Celltrion Inc

7.13.1 Celltrion Inc Profile

7.13.2 Celltrion Inc Main Business

7.13.3 Celltrion Inc Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.13.4 Celltrion Inc Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.13.5 Celltrion Inc Recent Developments

7.14 Amgen Limited

7.14.1 Amgen Limited Profile

7.14.2 Amgen Limited Main Business

7.14.3 Amgen Limited Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.14.4 Amgen Limited Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.14.5 Amgen Limited Recent Developments

7.15 Celgene Corporation

7.15.1 Celgene Corporation Profile

7.15.2 Celgene Corporation Main Business

7.15.3 Celgene Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.15.4 Celgene Corporation Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.15.5 Celgene Corporation Recent Developments

7.16 Sanofi

7.16.1 Sanofi Profile

7.16.2 Sanofi Main Business

7.16.3 Sanofi Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.16.4 Sanofi Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.16.5 Sanofi Recent Developments

7.17 Mylan N.V.

7.17.1 Mylan N.V. Profile

7.17.2 Mylan N.V. Main Business

7.17.3 Mylan N.V. Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.17.4 Mylan N.V. Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.17.5 Mylan N.V. Recent Developments

7.18 Samsung Bioepis

7.18.1 Samsung Bioepis Profile

7.18.2 Samsung Bioepis Main Business

7.18.3 Samsung Bioepis Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.18.4 Samsung Bioepis Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.18.5 Samsung Bioepis Recent Developments

7.19 Teva Pharmaceutical Industries Ltd.

7.19.1 Teva Pharmaceutical Industries Ltd. Profile

7.19.2 Teva Pharmaceutical Industries Ltd. Main Business

7.19.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Cancer Treatment Products, Services, and Solutions

7.19.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Cancer Treatment Revenue (US$ Million), 2021–2026

7.19.5 Teva Pharmaceutical Industries Ltd. Recent Developments

8 Industry Chain Analysis

8.1 Gastrointestinal Cancer Treatment Value Chain

8.2 Gastrointestinal Cancer Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Cost Structure

8.3 Midstream Analysis

8.4 Downstream (Customer) Analysis

8.5 Sales Model and Sales Channelss

8.5.1 Gastrointestinal Cancer Treatment Sales Model

8.5.2 Sales Channels

8.5.3 Gastrointestinal Cancer Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

Table of Figures

List of Tables

Table 1. Gastrointestinal Cancer Treatment Market Trends

Table 2. Gastrointestinal Cancer Treatment Market Drivers & Opportunities

Table 3. Gastrointestinal Cancer Treatment Market Challenges

Table 4. Gastrointestinal Cancer Treatment Market Restraints

Table 5. Global Gastrointestinal Cancer Treatment Revenue by Company (US$ Million), 2021–2026

Table 6. Global Gastrointestinal Cancer Treatment Revenue Market Share by Company (2021–2026)

Table 7. Key Companies’ R&D and Operations Footprint and Headquarters

Table 8. Key Companies Gastrointestinal Cancer Treatment Product Type

Table 9. Key Companies General Availability (GA) Timeline for Gastrointestinal Cancer Treatment

Table 10. Global Gastrointestinal Cancer Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Gastrointestinal Cancer Treatment revenue, 2025

Table 12. Mergers & Acquisitions and Expansion Plans

Table 13. Global Gastrointestinal Cancer Treatment Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)

Table 14. Global Gastrointestinal Cancer Treatment Sales Value by Type (US$ Million), 2021–2026

Table 15. Global Gastrointestinal Cancer Treatment Sales Value by Type (US$ Million), 2027–2032

Table 16. Global Gastrointestinal Cancer Treatment Sales Market Share in Value by Type (2021–2026)

Table 17. Global Gastrointestinal Cancer Treatment Sales Market Share in Value by Type (2027–2032)

Table 18. Global Gastrointestinal Cancer Treatment Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)

Table 19. Global Gastrointestinal Cancer Treatment Sales Value by Application (US$ Million), 2021–2026

Table 20. Global Gastrointestinal Cancer Treatment Sales Value by Application (US$ Million), 2027–2032

Table 21. Global Gastrointestinal Cancer Treatment Sales Market Share in Value by Application (2021–2026)

Table 22. Global Gastrointestinal Cancer Treatment Sales Market Share in Value by Application (2027–2032)

Table 23. Global Gastrointestinal Cancer Treatment Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032

Table 24. Global Gastrointestinal Cancer Treatment Sales Value by Region (US$ Million), 2021–2026

Table 25. Global Gastrointestinal Cancer Treatment Sales Value by Region (US$ Million), 2027–2032

Table 26. Global Gastrointestinal Cancer Treatment Sales Value by Region (%), 2021–2026

Table 27. Global Gastrointestinal Cancer Treatment Sales Value by Region (%), 2027–2032

Table 28. Key Countries/Regions Gastrointestinal Cancer Treatment Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032

Table 29. Key Countries/Regions Gastrointestinal Cancer Treatment Sales Value, (US$ Million), 2021–2026

Table 30. Key Countries/Regions Gastrointestinal Cancer Treatment Sales Value, (US$ Million), 2027–2032

Table 31. Eli Lilly Basic Information List

Table 32. Eli Lilly Description and Business Overview

Table 33. Eli Lilly Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 34. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Eli Lilly (2021–2026)

Table 35. Eli Lilly Recent Developments

Table 36. F. Hoffmann Basic Information List

Table 37. F. Hoffmann Description and Business Overview

Table 38. F. Hoffmann Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 39. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of F. Hoffmann (2021–2026)

Table 40. F. Hoffmann Recent Developments

Table 41. GlaxoSmithKline Basic Information List

Table 42. GlaxoSmithKline Description and Business Overview

Table 43. GlaxoSmithKline Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 44. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of GlaxoSmithKline (2021–2026)

Table 45. GlaxoSmithKline Recent Developments

Table 46. Merck Basic Information List

Table 47. Merck Description and Business Overview

Table 48. Merck Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 49. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Merck (2021–2026)

Table 50. Merck Recent Developments

Table 51. Novartis AG Basic Information List

Table 52. Novartis AG Description and Business Overview

Table 53. Novartis AG Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 54. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Novartis AG (2021–2026)

Table 55. Novartis AG Recent Developments

Table 56. Otsuka Holdings Basic Information List

Table 57. Otsuka Holdings Description and Business Overview

Table 58. Otsuka Holdings Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 59. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Otsuka Holdings (2021–2026)

Table 60. Otsuka Holdings Recent Developments

Table 61. Stryker Corporation Basic Information List

Table 62. Stryker Corporation Description and Business Overview

Table 63. Stryker Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 64. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Stryker Corporation (2021–2026)

Table 65. Stryker Corporation Recent Developments

Table 66. Boston Scientific Corporation Basic Information List

Table 67. Boston Scientific Corporation Description and Business Overview

Table 68. Boston Scientific Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 69. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Boston Scientific Corporation (2021–2026)

Table 70. Boston Scientific Corporation Recent Developments

Table 71. Johnson and Johnson Basic Information List

Table 72. Johnson and Johnson Description and Business Overview

Table 73. Johnson and Johnson Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 74. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Johnson and Johnson (2021–2026)

Table 75. Johnson and Johnson Recent Developments

Table 76. CONMED Corporation Basic Information List

Table 77. CONMED Corporation Description and Business Overview

Table 78. CONMED Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 79. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of CONMED Corporation (2021–2026)

Table 80. CONMED Corporation Recent Developments

Table 81. Bristol-Myers Squibb Basic Information List

Table 82. Bristol-Myers Squibb Description and Business Overview

Table 83. Bristol-Myers Squibb Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 84. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Bristol-Myers Squibb (2021–2026)

Table 85. Bristol-Myers Squibb Recent Developments

Table 86. Pfizer Basic Information List

Table 87. Pfizer Description and Business Overview

Table 88. Pfizer Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 89. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Pfizer (2021–2026)

Table 90. Pfizer Recent Developments

Table 91. Celltrion Inc Basic Information List

Table 92. Celltrion Inc Description and Business Overview

Table 93. Celltrion Inc Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 94. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Celltrion Inc (2021–2026)

Table 95. Celltrion Inc Recent Developments

Table 96. Amgen Limited Basic Information List

Table 97. Amgen Limited Description and Business Overview

Table 98. Amgen Limited Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 99. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Amgen Limited (2021–2026)

Table 100. Amgen Limited Recent Developments

Table 101. Celgene Corporation Basic Information List

Table 102. Celgene Corporation Description and Business Overview

Table 103. Celgene Corporation Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 104. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Celgene Corporation (2021–2026)

Table 105. Celgene Corporation Recent Developments

Table 106. Sanofi Basic Information List

Table 107. Sanofi Description and Business Overview

Table 108. Sanofi Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 109. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Sanofi (2021–2026)

Table 110. Sanofi Recent Developments

Table 111. Mylan N.V. Basic Information List

Table 112. Mylan N.V. Description and Business Overview

Table 113. Mylan N.V. Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 114. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Mylan N.V. (2021–2026)

Table 115. Mylan N.V. Recent Developments

Table 116. Samsung Bioepis Basic Information List

Table 117. Samsung Bioepis Description and Business Overview

Table 118. Samsung Bioepis Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 119. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Samsung Bioepis (2021–2026)

Table 120. Samsung Bioepis Recent Developments

Table 121. Teva Pharmaceutical Industries Ltd. Basic Information List

Table 122. Teva Pharmaceutical Industries Ltd. Description and Business Overview

Table 123. Teva Pharmaceutical Industries Ltd. Gastrointestinal Cancer Treatment Products, Services, and Solutions

Table 124. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Teva Pharmaceutical Industries Ltd. (2021–2026)

Table 125. Teva Pharmaceutical Industries Ltd. Recent Developments

Table 126. Revenue (US$ Million) in Gastrointestinal Cancer Treatment Business of Company 40 (2021–2026)

Table 127. Company 40 Recent Developments

Table 128. Key Raw Materials Lists

Table 129. Key Suppliers of Raw Materials Lists

Table 130. Gastrointestinal Cancer Treatment Downstream Customers

Table 131. Gastrointestinal Cancer Treatment Distributors List

Table 132. Research Programs/Design for This Report

Table 133. Key Data Information from Secondary Sources

Table 134. Key Data Information from Primary Sources

List of Figures

Figure 1. Gastrointestinal Cancer Treatment Product Picture

Figure 2. Global Gastrointestinal Cancer Treatment Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 4. Gastrointestinal Cancer Treatment Report Years Considered

Figure 5. Global Gastrointestinal Cancer Treatment Players Revenue Ranking (US$ Million), 2025

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Gastrointestinal Cancer Treatment Revenue in 2025

Figure 7. Gastrointestinal Cancer Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 8. Surgery Picture

Figure 9. Targeted Drugs Therapy Picture

Figure 10. Chemo Therapy Picture

Figure 11. Adjuvant Chemotherapy Picture

Figure 12. Radiation Therapy Picture

Figure 13. Global Gastrointestinal Cancer Treatment Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Gastrointestinal Cancer Treatment Sales Value Market Share by Type, 2025 & 2032

Figure 15. Product Picture of Hospitals

Figure 16. Product Picture of Clinics

Figure 17. Product Picture of Research Centers

Figure 18. Product Picture of Others

Figure 19. Global Gastrointestinal Cancer Treatment Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global Gastrointestinal Cancer Treatment Sales Value Market Share by Application, 2025 & 2032

Figure 21. North America Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 22. North America Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

Figure 23. Europe Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 24. Europe Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

Figure 25. Asia Pacific Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 26. Asia Pacific Gastrointestinal Cancer Treatment Sales Value by Subregion (%), 2025 vs 2032

Figure 27. South America Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 28. South America Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

Figure 29. Middle East & Africa Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 30. Middle East & Africa Gastrointestinal Cancer Treatment Sales Value by Country (%), 2025 vs 2032

Figure 31. Key Countries/Regions Gastrointestinal Cancer Treatment Sales Value (%), 2021–2032

Figure 32. United States Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 33. United States Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 34. United States Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 35. Europe Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 36. Europe Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 37. Europe Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 38. China Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 39. China Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 40. China Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 41. Japan Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 42. Japan Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 43. Japan Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 44. South Korea Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 45. South Korea Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 46. South Korea Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 47. Southeast Asia Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 48. Southeast Asia Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 49. Southeast Asia Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 50. India Gastrointestinal Cancer Treatment Sales Value (US$ Million), 2021–2032

Figure 51. India Gastrointestinal Cancer Treatment Sales Value by Type (%), 2025 vs 2032

Figure 52. India Gastrointestinal Cancer Treatment Sales Value by Application (%), 2025 vs 2032

Figure 53. Gastrointestinal Cancer Treatment Value Chain

Figure 54. Gastrointestinal Cancer Treatment Cost Structure

Figure 55. Channels of Distribution (Direct Sales, and Distribution)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

Related Reports

Gastrointestinal Cancer Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.
Published Date: 2024-01-24
Pages: 133
USD 3950.00
(Single User License)
Global Gastrointestinal Cancer Treatment Market Research Report 2024
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.
Published Date: 2024-01-31
Pages: 94
USD 2900.00
(Single User License)
Global Gastrointestinal Cancer Treatment Market Insights, Forecast to 2030
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.
Published Date: 2024-04-26
Pages: 118
USD 4900.00
(Single User License)
Global Gastrointestinal Cancer Treatment Market Research Report 2025
The global market for Gastrointestinal Cancer Treatment was valued at US$ 5049 million in the year 2024 and is projected to reach a revised size of US$ 11430 million by 2031, growing at a CAGR of 12.6% during the forecast period.
Published Date: 2025-02-27
Pages: 91
USD 2900.00
(Single User License)
Gastrointestinal Cancer Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gastrointestinal Cancer Treatment was estimated to be worth US$ 5049 million in 2024 and is forecast to a readjusted size of US$ 11430 million by 2031 with a CAGR of 12.6% during the forecast period 2025-2031.
Published Date: 2025-02-27
Pages: 122
USD 3950.00
(Single User License)
Global Gastrointestinal Cancer Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Gastrointestinal Cancer Treatment market size was US$ 5049 million in 2024 and is forecast to a readjusted size of US$ 11430 million by 2031 with a CAGR of 12.6% during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 108
USD 4250.00
(Single User License)
Global Gastrointestinal Cancer Treatment Market Research Report 2026
The global Gastrointestinal Cancer Treatment market was valued at US$ 5619 million in 2025 and is anticipated to reach US$ 12720 million by 2032, at a CAGR of 12.6% from 2026 to 2032.
Published Date: 2026-04-27
Pages: 124
USD 2900.00
(Single User License)

Gastrointestinal Cancer Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.
Published: 2024-01-24
Pages: 133
USD 3950.00 (Single User License)
Global Gastrointestinal Cancer Treatment Market Research Report 2024
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.
Published: 2024-01-31
Pages: 94
USD 2900.00 (Single User License)
Global Gastrointestinal Cancer Treatment Market Insights, Forecast to 2030
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems. This report focus on Gastrointestinal Cancer Treatment market.
Published: 2024-04-26
Pages: 118
USD 4900.00 (Single User License)
Global Gastrointestinal Cancer Treatment Market Research Report 2025
The global market for Gastrointestinal Cancer Treatment was valued at US$ 5049 million in the year 2024 and is projected to reach a revised size of US$ 11430 million by 2031, growing at a CAGR of 12.6% during the forecast period.
Published: 2025-02-27
Pages: 91
USD 2900.00 (Single User License)
Gastrointestinal Cancer Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gastrointestinal Cancer Treatment was estimated to be worth US$ 5049 million in 2024 and is forecast to a readjusted size of US$ 11430 million by 2031 with a CAGR of 12.6% during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 122
USD 3950.00 (Single User License)
Global Gastrointestinal Cancer Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Gastrointestinal Cancer Treatment market size was US$ 5049 million in 2024 and is forecast to a readjusted size of US$ 11430 million by 2031 with a CAGR of 12.6% during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 108
USD 4250.00 (Single User License)
Global Gastrointestinal Cancer Treatment Market Research Report 2026
The global Gastrointestinal Cancer Treatment market was valued at US$ 5619 million in 2025 and is anticipated to reach US$ 12720 million by 2032, at a CAGR of 12.6% from 2026 to 2032.
Published: 2026-04-27
Pages: 124
USD 2900.00 (Single User License)